Koruth R - Search Results

1

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV. Schadendorf D, et al. Among authors: koruth r. Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27. Lancet Oncol. 2019. PMID: 30928620 Clinical Trial.

2

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.

Gerbasi ME, Stellato D, Ghate SR, Ndife B, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE. Gerbasi ME, et al. Among authors: koruth r. J Med Econ. 2019 Dec;22(12):1243-1252. doi: 10.1080/13696998.2019.1635487. Epub 2019 Aug 4. J Med Econ. 2019. PMID: 31223037 Free article.

3

Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.

Stellato D, Gerbasi ME, Ndife B, Ghate SR, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE. Stellato D, et al. Among authors: koruth r. J Manag Care Spec Pharm. 2019 Nov;25(11):1227-1237. doi: 10.18553/jmcp.2019.25.11.1227. J Manag Care Spec Pharm. 2019. PMID: 31663466 Free PMC article.

4

Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.

Sharma R, Koruth R, Kanters S, Druyts E, Tarhini A. Sharma R, et al. Among authors: koruth r. J Comp Eff Res. 2019 Dec;8(16):1349-1363. doi: 10.2217/cer-2019-0061. Epub 2019 Nov 28. J Comp Eff Res. 2019. PMID: 31778073 Free article.

5

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Mohr P, et al. Among authors: koruth r. Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015. Melanoma Manag. 2019. PMID: 31871622 Free PMC article.

6

Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019.

Garrison LP, Jiao B, Elsisi Z, Yehoshua A, Koruth R, Kreter B, Grueger J. Garrison LP, et al. Among authors: koruth r. Value Health. 2024 Apr 23:S1098-3015(24)02343-X. doi: 10.1016/j.jval.2024.04.011. Online ahead of print. Value Health. 2024. PMID: 38663800 Free article.

7

Method for quantitative refolding of the link module from human TSG-6.

Kahmann JD, Koruth R, Day AJ. Kahmann JD, et al. Among authors: koruth r. Protein Expr Purif. 1997 Apr;9(3):315-8. doi: 10.1006/prep.1996.0694. Protein Expr Purif. 1997. PMID: 9126602

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page